Akero Therapeutics Inc., a clinical-stage company headquartered in South San Francisco, California, is dedicated to developing innovative treatments for patients with serious metabolic diseases. The company announced that management will present at the BofA Securities 2024 Health Care Conference on May 14th, 2024, in Las Vegas, NV. The presentation will take place at 5:00 p.m. P.T. and will be available for viewing via a live webcast on the company’s investor relations section of their website, www.akerotx.com. After the live webcast, an archived replay will also be accessible on the website.
Akero Therapeutics is focused on addressing the high unmet medical needs of patients with metabolic diseases, including MASH (Metabolic Associated Fatty Liver Disease). Their lead product candidate, EFX (entrectinib), is currently undergoing evaluation in a 96-week Phase 2b clinical trial called the SYMMETRY study. This trial involves patients with compensated cirrhosis due to MASH (F4 fibrosis). Additionally, the company has two ongoing Phase 3 clinical trials: the SYNCHRONY Histology study in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and the SYNCHRONY Real-World study in patients with MASH (F1-F3 fibrosis) or MASLD (Metabolic Associated Steatohepatitis Due to Lipopolysaccharide Exposure).
In addition to these trials, Akero Therapeutics has also announced plans to begin a third clinical trial known as the SYNCHRONY Outcomes study in the second quarter of 2024. This study will focus on patients with compensated cirrhosis due to MASH (F4 fibrosis), and is based on the positive results of two Phase 2b trials: the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akero Therapeutics is committed to advancing its pipeline of treatments for metabolic diseases and improving patient outcomes for those affected by these debilitating conditions. For more information about Akero Therapeutics and its ongoing clinical trials, visit www.akerotx.com or follow them on LinkedIn and Twitter. For investor inquiries
